America’s first transgender suicide hotline is up and running
The new hotline is staffed entirely by transgender people and dedicated to addressing and supporting members of the trans community in mental health crises.
Mental health & addiction
New study shows psychedelic mushrooms are as effective as antidepressants
Psilocybin performed about as well as the SSRI escitalopram as a treatment for moderate-to-severe major depressive disorder, according to a new double-blinded, randomized experiment.
Oakland to launch alternative response program for nonviolent 911 calls
Following successful alternative policing programs in Denver and Newark, Oakland, California is the latest city to adopt such a program with an initiative to redirect nonviolent, noncriminal calls to mobile teams of civilians.
First Phase 3 trial data for MDMA therapy sets path for approval in the U.S.
The extremely promising data are the first Phase 3 results to be revealed for any psychedelic-based therapy, paving the way for a landmark US Food and Drug Administration (FDA) approval in 2023.
American Psychological Association opposes transgender conversion “therapy” in historic statement
“Transgender or nonbinary gender identities are normal variations in human expression of gender. Attempts to force people to conform with rigid gender identities can be harmful to their mental health and well-being.”
MDMA proves a promising alcoholism treatment in world-first trial
A small open-label trial is the first to test MDMA therapy as a treatment for addiction and the results suggest it is safe, well-tolerated and significantly more effective than any current treatment for alcoholism.
World-first biomarker test can predict depression and bipolar disorder
Australian scientists have developed and validated a world-first test that is claimed to accurately measure levels of a brain protein known to be associated with depression and bipolar disorder.
Somerville, Massachusetts decriminalizes naturally occurring psychedelics
The Somerville City Council voted 9-0 to decriminalize the possession of entheogenic plants, including psilocybin mushrooms and ibogaine.
Experimental Alzheimer’s drug delivers promising Phase 2 trial results
According to the new data from pharmaceutical company Eli Lilly, the antibody donanemab slowed cognitive decline by 32% compared to a placebo.
MDMA-assisted couples therapy shows promising initial results in landmark pilot trial
The new study reports the addition of MDMA to the couples therapy protocol resulted in effects that were, “on par with, or greater than, those achieved with CBCT [cognitive-behavioral conjoint therapy] alone.”